Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003871 · ClinicalTrials.gov registry record · Phase 2
PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 10
- Study locations
NCT00003871: Completed Phase 2 study of Prostate Cancer, sponsored by Eastern Cooperative Oncology Group.
NCT00003871 is a Phase 2 study of Prostate Cancer that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 60 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003871, a Phase 2 study of Prostate Cancer, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 10
- Study locations
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of different regimens of PSA vaccines in treating patients who have advanced prostate cancer.
Conditions Studied
Interventions
- BIOLOGICAL fowlpox virus vaccine vector
- BIOLOGICAL recombinant vaccinia prostate-specific antigen vaccine
Study Locations (10)
Indiana
- Indiana University Cancer Center - Indianapolis
- Veterans Affairs Medical Center - Indianapolis (Roudebush) - Indianapolis
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- University of Pittsburgh Cancer Institute - Pittsburgh
Wisconsin
- Veterans Affairs Medical Center - Madison - Madison
- University of Wisconsin Comprehensive Cancer Center - Madison
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
New Jersey
- Cancer Institute of New Jersey - New Brunswick
New York
- Albert Einstein Comprehensive Cancer Center - The Bronx
Tennessee
- Vanderbilt Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 1999-09-24 |
| Phase | Phase 2 |
What the finished NCT00003871 record still lists
NCT00003871 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which fowlpox virus vaccine vector is the first listed.
NCT00003871 lists 10 locations in 7 states (Indiana, Pennsylvania, Wisconsin).
Frequently Asked Questions
What is clinical trial NCT00003871 about?
NCT00003871 is a clinical study titled "PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of different regimens of PSA vaccines in treating patients who have advanced prostate cancer.
What is the current status of trial NCT00003871?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 1999-09-24.
What conditions does trial NCT00003871 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00003871?
The interventions under investigation include: fowlpox virus vaccine vector (BIOLOGICAL), recombinant vaccinia prostate-specific antigen vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003871?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003871 being conducted?
This trial has 10 study locations across Indiana, Massachusetts, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003871's enrollment target sits among peer trials
60 421st of 735 higher than 293 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI